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Purpose: Patients with severe eosinophilic asthma
often experience recurrent asthma exacerbations de-
spite intensive inhaled corticosteroid therapy. In 2
previous double-blind studies (MENSA [NCT0169
1521] and SIRIUS [NCT01691508]), treatment with
intravenous or subcutaneous mepolizumab was associ-
ated with signiﬁcantly reduced annualized exacerbation
rates and oral corticosteroid (OCS) requirements
compared with placebo. The purpose of this study
was to assess the long-term safety and efﬁcacy of
subcutaneous mepolizumab treatment in patients with
severe eosinophilic asthma.
Methods: COSMOS was a 52-week, open-label
extension study in patients who received mepolizumab
or placebo in MENSA or SIRIUS. Patients received
subcutaneous mepolizumab regardless of prior treat-
ment allocation and continued to receive appropriate
standard-of-care asthma therapy throughout. The pri-
mary objective was to assess the long-term safety of
mepolizumab; end points included adverse events (AEs)
and serious AEs (SAEs). Efﬁcacy assessments included
the annualized exacerbation rate and durability of
response (deﬁned as the exacerbation rate and OCS*Current afﬁliation: Respiratory and Allergic Diseases, Genen-
tech, South San Francisco, California.
2058dose reduction when combined with MENSA and
SIRIUS data, respectively).
Findings: In total, 558 (86%; previous mepolizumab:
358; previous placebo: 200) and 94 (14%; previous
mepolizumab: 58, previous placebo: 36) patients
experienced on-treatment AEs and SAEs, respectively.
No fatal AEs were reported. Totals of 13 (2%) and
29 (4%) patients experienced systemic and local site
reactions, respectively. There were no reports
of mepolizumab-related anaphylaxis. Mepolizumab
treatment was shown to exert a durable response,
with patients who previously received mepolizumab
in MENSA or SIRIUS maintaining reductions in
exacerbation rate and OCS dosing throughout
COSMOS. Patients who previously received placebo
in MENSA or SIRIUS demonstrated improvements in
these end points following treatment with mepolizumab
in COSMOS.
Implications: These data demonstrate a favorable
safety proﬁle of mepolizumab and indicate a durable
and stable effect over time, supporting long-term
treatment in patients with severe eosinophilic asthma.http://dx.doi.org/10.1016/j.clinthera.2016.07.010
0149-2918/$ - see front matter
& 2016 The Authors. Published by Elsevier HS Journals, Inc. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Severe asthma is a heterogeneous condition including
several clinical phenotypes that differ in severity
and response to therapy.1,2 One such phenotype is
severe eosinophilic asthma, which is characterized by
eosinophilic airway inﬂammation.1,2 These patients
often experience recurrent asthma exacerbations
despite intensive asthma therapy with high-dose
inhaled corticosteroids or oral corticosteroids (OCSs)
plus controllers,3 leading to increased morbidity and
mortality.4,5
Mepolizumab is a humanized anti–interleukin-5
monoclonal antibody that was recently approved in
several countries/regions, including Australia, Japan,
Canada, Europe, and the United States, for the treat-
ment of severe eosinophilic asthma in adults. The
efﬁcacy of mepolizumab in this patient population has
been demonstrated in 3 randomized, controlled
clinical trials, SIRIUS (Steroid Reduction with
Mepolizumab Study), MENSA (Mepolizumab as Ad-
junctive Therapy in Patients with Severe Asthma), and
DREAM (Dose Ranging Efﬁcacy and Safety with
Mepolizumab).6–8
The 52-week, double-blind, placebo-controlled
DREAM study (ClinicalTrials.gov identiﬁer: NCT
01000506) assessed asthma exacerbation rates in
patients with severe eosinophilic asthma receiving 1
of 3 doses of intravenous mepolizumab or placebo;
there were signiﬁcant reductions in the rate of asthma
exacerbations of 39% to 52% across all intravenous
mepolizumab treatment groups compared with placebo.8
In the pivotal 32-week, double-blind MENSA study
(ClinicalTrials.gov identiﬁer: NCT01691521), treatment
with intravenous or subcutaneous mepolizumab within
this patient population was associated with signiﬁcant
reductions in annualized exacerbations, by 47%
and 53%, respectively, compared with placebo.7
Furthermore, in the 24-week, double-blind, placebo-
controlled SIRIUS study (ClinicalTrials.gov identiﬁer:
NCT01691508), subcutaneous mepolizumab was asso-
ciated with a reduced need for treatment with OCSs,September 2016reduced annualized exacerbation rates, and im-
proved asthma control.6 This reduction in OCS use
is of importance because treatment with OCSs has a
considerable impact on patients’ lives owing to the
associated corticosteroid-related adverse effects.9–11
While all 3 studies reported the prevalence of
adverse events (AEs) and assessed basic safety
variables, the long-term safety and durability of the
response to subcutaneous mepolizumab in patients
with severe eosinophilic asthma are not fully
established.
This article describes COSMOS, the ﬁrst com-
pleted, dedicated long-term safety study (a 52-week,
open-label extension of the MENSA and SIRIUS
studies) of subcutaneous mepolizumab, conducted in
patients with severe eosinophilic asthma. In addition,
the durability and stability of the response to treat-
ment with subcutaneous mepolizumab were assessed
in terms of reductions in exacerbations and OCS
dose.PATIENTS AND METHODS
Study Design
COSMOS was a 52-week, multicenter, open-label,
Phase IIIb study that assessed the safety of mepolizumab
100 mg SC in patients with severe eosinophilic
asthma. The study was conducted between May
2013 and March 2015, at 139 centers across 19
countries. The study was performed in accordance
with the Good Clinical Practice guidelines, the ethics
principles outlined in the Declaration of Helsinki
2008, and in accordance with institutional review
board approvals/processes.
Patients completing the MENSA or SIRIUS study
(both reported separately)6,7 were given the opportu-
nity to provide consent for participation in this open-
label extension study in which all participants received
mepolizumab regardless of treatment allocation in
those 2 double-blind studies. The last visit in either
previous study served as the baseline visit for the
present study (Figure 1).
In COSMOS, mepolizumab 100 mg SC was
administered at baseline (visit 1; week 0), and then
every 4 weeks for a total of 48 weeks, as an add-on to
appropriate standard of care that could be adjusted
at the physician’s discretion. Fourteen visits were
completed to week 52, with a follow-up visit 12
weeks after each patient’s last dose.2059
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Figure 1. Duration and patient contribution
to the double-blind and open-label
periods. The schematic diagram
represents the contribution of
MENSA7 and SIRIUS6 patients to
the COSMOS study. IV, Intravenous;
SC, subcutaneous.
Clinical TherapeuticsPatients
Eligible patients were Z12 years of age, had
completed the MENSA or SIRIUS study,6,7 and were
being treated with an inhaled corticosteroid and an-
other asthma controller medication throughout either
study. Patients were expected to continue on controller
therapy throughout the duration of this study. All
patients provided written informed consent prior to
the performance of any study-speciﬁc procedures.
Female patients of childbearing potential were
required to commit to consistent and correct use of
acceptable birth control methods for the duration of
the study, and for 4 months after the last adminis-
tration of study drug; pregnancy testing was
performed in all female patients prior to enrollment,
during each scheduled study visit prior to administra-
tion of study drug, and during the follow-up visit.
Patients in France were eligible for inclusion only if
they were afﬁliated with, or a beneﬁciary of, a social
security category.
Exclusion criteria included the following occur-
rences during the MENSA or SIRIUS study: a study
medication–related hypersensitivity reaction that led
to withdrawal; a clinically signiﬁcant change in health
status that the investigator thought might make the
patient unsuitable for participation in this study; a
malignancy; a serious AE (SAE) judged by the inves-
tigator as possibly related to study medication; an2060alanine or aspartate aminotransferase, or alkaline
phosphatase, level Z2-fold the upper limit of normal;
and/or a bilirubin level Z1.5-fold the upper limit of
normal. Other exclusion criteria included pregnancy;
baseline ECG values indicative of a clinically signiﬁ-
cant abnormality; being a current smoker; and/or a
positive hepatitis B surface antigen result at visit 1.
The use of other monoclonal antibodies, including
omalizumab, as well as other investigational drugs
and experimental anti-inﬂammatory drugs (nonbio-
logics) was prohibited.
Procedures
Patient Assessments
Demographic information and medical history,
including asthma therapy history, were assessed
at baseline (visit 1; week 0). Concurrent medications
(including OCS dose) were assessed at every clinic
visit.
Safety Assessments
The occurrences of AEs and SAEs, including car-
diovascular (CV) events (adjudicated by a clinical end
point committee), investigator-deﬁned systemic aller-
gic and nonallergic reactions, and local site reactions
were reported at all visits. The following prespeciﬁed
events were adjudicated by the clinical end point
committee: cerebrovascular events, including stroke
and transient ischemic attack; congestive heart failure;
deep vein thrombosis; myocardial infarction/unstable
angina; peripheral arterial thromboembolism; and
all-cause death. All systemic reactions were assessed
for anaphylaxis using the diagnostic criteria deﬁned
by Sampson et al.12 Twelve-lead ECGs were assessed
at baseline and at weeks 28, 52 (exit visit), and 60
(or 12 weeks following last dose; follow-up visit).
Vital signs were assessed at all visits, and clinical
laboratory variables were assessed at various time
points.
Efficacy Assessments
Assessment for exacerbations occurred at every
clinic visit. The 5-item Asthma Control Questionnaire
(ACQ-5) score (scale: 0 ¼ totally controlled, to
6 ¼ severely uncontrolled) was assessed at baseline
and at weeks 4, 16, 28, 40, 52 (exit visit), and 60
(or 12 weeks following last dose; follow-up). Forced
expiratory volume in 1 second (FEV1) was assessed at
baseline and at weeks 16, 28, and 52 (exit visit).Volume 38 Number 9
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Figure 2. Summary of patient disposition.
AT ¼ as-treated; PMG ¼ previous
mepolizumab group; PPG ¼ previous
placebo group.
N. Lugogo et al.Blood eosinophil count was assessed at baseline and at
weeks 4, 16, 28, 52, and 60 (or 12 weeks following
last dose; follow-up).
Immunogenicity Assessments
Immunogenicity testing included 2 assays: (1) a
binding antibody assay for antidrug antibody (ADA);
and (2) a neutralizing antibody assay in patients who
tested positive on the ADA assay. These assessments
were conducted at baseline and at weeks 52 (exit visit)
and 60 (or 12 weeks following last dose; follow-up).
Study Objectives
The primary objective of the study was to describe
the long-term safety proﬁle of mepolizumab in pa-
tients with severe eosinophilic asthma. The secondary
objective was to evaluate the efﬁcacy of long-term
mepolizumab treatment in terms of a range of clinical
markers of asthma control, including the annualized
rate of exacerbations, ACQ-5 score, and FEV1.
Durability of response, deﬁned as the rate of exacer-
bations and OCS dose, was also assessed; however,
this end point was not prespeciﬁed in the protocol and
was assessed post hoc.
Statistical Analysis
No sample size was calculated; the study popula-
tion was determined by the number of patients
randomized into the MENSA or SIRIUS study who
were eligible for COSMOS. The as-treated popula-
tion, consisting of all patients who received at least 1
dose of open-label mepolizumab, was the population
used for all analyses. Data are summarized using
appropriate descriptive statistics (means/geometric
means, SDs, medians, and ranges).
AEs were summarized using the Medical Diction-
ary for Regulatory Activities primary System Organ
Class and preferred terms. The annualized rate of
exacerbations was estimated using a negative binomial
generalized linear model, with a log-link function,13
from which the estimated rate per year and associated
95% CI were calculated. Time to ﬁrst exacerbation
was summarized using Kaplan–Meier estimates.
ACQ-5 score and FEV1 were assessed as changes
from baseline. For blood eosinophil counts, values
below the lower limit of quantiﬁcation were imputed
with half of the lower limit of quantiﬁcation prior to
log-transformation. Post hoc analysis of durability of
response was conducted by combining the dataSeptember 2016from this open-label study (COSMOS) with those
from the previous double-blind studies (MENSA
and SIRIUS6,7) in patients who completed 2 studies.
All statistical analyses were performed using SAS
version 9.3 (SAS Institute, Cary, North Carolina).RESULTS
In total, 651 patients were enrolled into COSMOS
(525 [91%] and 126 [93%] of those randomized in
MENSA and SIRIUS, respectively6,7 and were in-
cluded in the as-treated population. Of these, 414
patients (64%) had previously received mepolizumab
intravenously or subcutaneously in MENSA or
SIRIUS (previous mepolizumab group [PMG]), and
237 (36%) had previously received placebo (previous
placebo group [PPG]) in MENSA or SIRIUS (and
therefore received mepolizumab for the ﬁrst time at
visit 1 of COSMOS). Sixty-six patients (10%) were
withdrawn from the study. The most common reasons
for withdrawal were a lack of efﬁcacy (19 patients
[3%]), patient’s decision (14 patients [2%]), AEs (11
patients [2%]), physician’s decision (9 patients [1%]),
and protocol deviation patients (8 [1%], which in-
cluded 4 patients [o1%] who became pregnant and 3
patients [o1%] due to lack of adherence). Baseline2061
Clinical Therapeuticscharacteristics were generally comparable between
patients who withdrew and the total patient popula-
tion, although the mean baseline ACQ-5 score and
prebronchodilator FEV1 value were slightly worse
in those who withdrew. Patient disposition is sum-
marized in Figure 2.
Overall, patients’ demographic and clinical charac-
teristics at COSMOS baseline were well-balanced
between previous treatment groups (Table I). Differ-
ences in ACQ-5 scores, lung function, and blood
eosinophil counts between the PPG and PMG reﬂected
the treatments originally received during MENSA and
SIRIUS (ie, mepolizumab or placebo).
By the end of COSMOS, a total of 691 patients had
received mepolizumab treatment in MENSA, SIRIUS,
or COSMOS. Of these, 614 (89%) and 362 (52%)
patients had received continuous mepolizumab treat-
ment for at least 12 and 18 months, respectively. The
median cumulative exposure to mepolizumab was
17.6 months (range, 1–22 months).
For the primary outcome of long-term safety, AEs
were reported in 562 patients (86%). The majority of
these patients (558 [86%]) experienced on-treatment
AEs. Across the whole study population, the on-
treatment AEs most commonly reported were naso-
pharyngitis (196 patients [30%]), upper respiratory
tract infection (101 [16%]), and worsening or ex-
acerbation of asthma (90 [14%]). In total, 123
patients (19%) had AEs considered as related to the
study treatment. Similar numbers of AEs were ob-
served between patients who had previously received
mepolizumab (PMG) and patients who had previ-
ously received placebo (PPG). Safety data are sum-
marized in Table II.
In the overall population, SAEs were reported in
105 patients (16%), with 94 patients (14%) reporting
an SAE while on treatment (Table II). The most
common on-treatment SAEs in all patients included
worsening or exacerbation of asthma (38 patients
[6%]), pneumonia (4 patients [o1%]), and atrial
ﬁbrillation (3 patients [o1%]) (Table II). Two
patients (o1%) experienced SAEs considered related
to the study treatment (type IV hypersensitivity
reaction in the PMG, which was resolved, and
spontaneous abortion in the PPG). Similar numbers
of SAEs were reported in the PMG and the PPG
(Table II). No fatal SAEs were reported during the
study. A total of 15 patients (2%) experienced CV
events, of whom 3 patients (o1%) experienced the2062prespeciﬁed adjudicated CV events (stroke [PMG],
deep vein thrombosis [PMG], and myocardial
infarction requiring hospitalization [PPG]) as
assessed by the clinical end point committee (Table II).
Systemic and local site reactions were reported in
13 (2%) and 29 (4%) patients, respectively. Slightly
higher numbers of systemic reactions (7 [3%] vs 6
[1%]) and local site reactions (15 [6%] vs 14 [3%])
were observed in the PPG than in the PMG, respec-
tively (Table II). There were no reports of anaphylaxis
considered related to treatment with mepolizumab.
The percentages of patients with abnormal ECG
values throughout the study were similar between
groups, with few clinically signiﬁcant changes from
baseline observed. Postbaseline vital sign and clinical
laboratory measurements were generally similar to
baseline values; few clinical chemistry values outside
the normal range were observed at postbaseline visits.
During COSMOS, on-treatment asthma exacerba-
tions were observed in 311 patients (48%) (rate per
annum, 0.93), with 59 patients (9%) requiring hospi-
talization or an emergency department visit, and 39
(6%) requiring hospitalization only (Table III).
The probability of experiencing at least 1 exacer-
bation increased throughout the treatment period,
from 24.2% (95% CI, 21.0%–27.7%) at week 16,
to 49.1% (95% CI, 45.2%–53.1%) at week 52
(see Figure E1 and Table E1 in the online version
at doi:10.1016/j.clinthera.2016.07.010). All exacer-
bation data were similar between the PMG and the
PPG (Table III) (see Figure E1 and Table E1 in the
online version at doi:10.1016/j.clinthera.2016.07.010
and were consistent with those from the double-blind
studies.
For ACQ-5 and FEV1, the improvements from
baseline observed in the PMG during previous
double-blind treatment were maintained through
week 52 of the open-label period (Table III). In the
PPG, for both outcomes, improvements were observed
at the ﬁrst postbaseline assessment and were
maintained through week 52 (Table III). Following
the discontinuation of mepolizumab treatment (last
dose at week 48), higher ACQ-5 scores were reported
at week 60 (follow-up) in both the PMG and PPG,
indicating reduced asthma control compared with that
at week 52.
Blood eosinophil count reductions demonstrated in
the PMG during double-blind treatment were main-
tained throughout the open-label study (Table III). InVolume 38 Number 9
Table I. Patients’ demographic and clinical characteristics at baseline (as-treated population).* Data are given
as number (%) of patients unless otherwise noted.
Characteristic PPG (n ¼ 237) PMG (n ¼ 414) All Patients (n ¼ 651)
Age, mean (SD), y 50.4 (13.4) 51.6 (14.1) 51.1 (13.9)
Female 125 (53) 235 (57) 360 (55)
Race
White 192 (81) 338 (82) 530 (81)
Asian 38 (16) 61 (15) 99 (15)
Other 7 (3) 15 (4) 22 (3)
Non-Hispanic/Latino ethnicity 220 (93) 381 (92) 601 (92)
Body mass index n ¼ 236 n ¼ 411 n ¼ 647
Mean (SD), kg/m2 28.2 (5.7) 27.9 (5.9) 28.0 (5.8)
Duration of asthma, mean (SD), y 20.1 (14.7) 20.3 (13.4) 20.2 (13.9)
Allergic rhinitis or hay fever 116 (49) 195 (47) 311 (48)
ACQ-5 score† n ¼ 220 n ¼ 390 n ¼ 610
Mean (SD) 1.76 (1.13) 1.25 (1.10) 1.44 (1.14)
Median (min, max) 1.60 (0.0, 5.2) 1.00 (0.0, 6.0) 1.20 (0.0, 6.0)
Prebronchodilator baseline FEV1, mL n ¼ 237 n ¼ 412 n ¼ 649
Mean (SD) 1957 (668) 2010 (733) 1991 (710)
Median (min, max) 1880 (450, 4650) 1920 (480, 4780) 1910 (450, 4780)
Prebronchodilator FEV1/FVC ratio n ¼ 237 n ¼ 412 n ¼ 649
Mean (SD) 0.64 (0.12) 0.66 (0.12) 0.65 (0.12)
Median (min, max) 0.64 (0.3, 0.9) 0.67 (0.3, 1.0) 0.66 (0.3, 1.0)
Reversibility of FEV1 n ¼ 217 n ¼ 379 n ¼ 596
Mean (SD), % 17.2 (18.9) 15.9 (17.2) 16.4 (17.9)
Concurrent therapy
ICS 237 (100) 409 (99) 646 (499)
LABA 231 (97) 406 (98) 637 (98)
LTRA 111 (47) 184 (44) 295 (45)
Xanthine 49 (21) 79 (19) 128 (20)
LAMA 30 (13) 66 (16) 96 (15)
Blood eosinophil count, cells/mL n ¼ 230 n ¼ 400 n ¼ 630
Geometric mean (SD logs) 280 (0.926) 50 (0.914) 90 (1.248)
Median (min, max) 320 (10, 1900) 50 (10, 900) 80 (10, 1900)
ACQ-5 ¼ 5-item Asthma Control Questionnaire; FEV1 ¼ forced expiratory volume in 1 second; FVC ¼ forced vital capacity;
ICS ¼ inhaled corticosteroid; min ¼ minimum; max ¼ maximum; LABA ¼ long-acting β-agonist; LAMA ¼ long-acting
muscarinic antagonist; LTRA ¼ leukotriene receptor agonist; PMG ¼ previous mepolizumab group; PPG ¼ previous placebo
group .
*Table presents patients’ characteristics when they commenced COSMOS.
†Scale scores: 0 ¼ totally controlled, to 6 ¼ severely uncontrolled.
N. Lugogo et al.the PPG, blood eosinophil counts (geometric mean
[SD log]) were reduced from 280 (0.926) cells/mL at
baseline (Table I) to 60 (0.886) cells/mL at week 4. A
similar blood eosinophil count was maintained through
week 52 (Table III). Following the discontinuation ofSeptember 2016mepolizumab treatment (last dose at week 48), blood
eosinophil counts increased to 160 (1.117) and
160 (1.141) cells/mL in the PPG and PMG popu-
lations, respectively, at week 60 (follow-up). The
antihistamines ketotifen fumarate and rupatadine,2063
Table II. Summary of adverse events (AEs), including cardiovascular (CV) events and systemic and local
reactions (as-treated population). Data are given as number (%) of patients unless otherwise noted.
Parameter
PPG
(n ¼ 237)
PMG
(n ¼ 414)
All Patients
(N ¼ 651)
Any AE* 202 (85) 360 (87) 562 (86)
On-treatment 200 (84) 358 (86) 558 (86)
Most common (occurring in Z10% of patients)
Nasopharyngitis 82 (35) 114 (28) 196 (30)
Upper respiratory tract infection 40 (17) 61 (15) 101 (16)
Asthma† 36 (15) 54 (13) 90 (14)
Bronchitis 34 (14) 46 (11) 80 (12)
Headache 28 (12) 60 (14) 88 (14)
Sinusitis 23 (10) 43 (10) 66 (10)
Related to study treatment 48 (20) 75 (18) 123 (19)
Any SAE 41 (17) 64 (15) 105 (16)
On-treatment 36 (15) 58 (14) 94 (14)
Related to study treatment¶ 1 (o1) 1 (o1) 2 (o1)
Most common (occurring in Z2 patients)
Asthma† 16 (7) 22 (5) 38 (6)
Atrial ﬁbrillation 3 (1) 0 3 (o1)
Pneumonia 2 (o1) 2 (o1) 4 (o1)
Bronchitis 2 (o1) 0 2 (o1)
Appendicitis 1 (o1) 1 (o1) 2 (o1)
Upper respiratory tract infection 1 (o1) 1 (o1) 2 (o1)
Diverticulitis 0 2 (o1) 2 (o1)
Any fatal SAE 0 0 0
Any CV event 6 (3) 9 (2) 15 (2)
Any prespeciﬁed adjudicated CV event‡ 1 (o1) 2 (o1) 3 (o1)
Myocardial infarction requiring hospitalization 1 (o1) 0 1 (o1)
Deep vein thrombosis 0 1 (o1) 1 (o1)
Stroke 0 1 (o1) 1 (o1)
Any systemic reaction 7 (3) 6 (1) 13 (2)
Any injection-related reaction (nonallergic) 5 (2) 2 (o1) 7 (1)
Hypersensitivity 1 (o1) 3 (o1) 4 (o1)
Type IV hypersensitivity 1 (o1) 2 (o1) 3 (o1)
Local injection-site reaction 15 (6) 14 (3) 29 (4)
PMG ¼ previous mepolizumab group; PPG ¼ previous placebo group; SAE ¼ serious adverse event.
*Listed according to Medical Dictionary for Regulatory Activities terminology; other terms may be used.
†Asthma reported as an AE means worsening or exacerbation of asthma.
‡As assessed by the clinical end point committee.
¶The following: SAEs related to treatment (investigator assessment) included Type IV hypersensitivity (PMG) and
spontaneous abortion (PPG).
Clinical Therapeuticswhich have modest anti-eosinophilic properties, were
taken by a small number of patients during the study.
Ketotifen fumarate was taken during treatment by20644 patients in the PPG group and 1 in the PMG group.
Rupatadine or rupatadine fumarate was taken during
treatment by 8 patients (4 in each group).Volume 38 Number 9
Table III. Summary of efficacy data (as-treated population).
Parameter
PPG
(n ¼ 237)
PMG
(n ¼ 414)
All Patients
(N ¼ 651)
On-treatment exacerbations*
All exacerbations
Patients, no. (%) 120 (51) 191 (46) 311 (48)
Exacerbations 246 408 654
Exacerbation rate per annum (95% CI) 0.99 (0.83–1.18) 0.90 (0.78–1.04) 0.93 (0.83–1.04)
Exacerbations requiring hospitalization or ED visit
Patients, no. (%) 26 (11) 33 (8) 59 (9)
Exacerbations 38 57 95
Exacerbations requiring hospitalization
Patients, no. (%) 16 (7) 23 (6) 39 (6)
Exacerbations 25 40 65
ACQ-5 score, change from baseline†,‡
Week 4 n = 218 n = 385 n = 603
Mean (SD) –0.28 (0.88) 0.01 (0.75) –0.09 (0.81)
Median (min, max) –0.20 (–3.4, 2.6) 0.00 (–3.0, 3.6) 0.00 (–3.4, 3.6)
Week 16 n = 215 n = 377 n = 592
Mean (SD) –0.46 (0.91) 0.09 (0.87) –0.11 (0.92)
Median (min, max) –0.40 (–3.6, 3.0) 0.00 (–2.6, 4.2) 0.00 (–3.6, 4.2)
Week 28 n = 212 n = 365 n = 577
Mean (SD) –0.33 (1.10) 0.12 (0.94) –0.05 (1.02)
Median (min, max) –0.20 (–3.0, 3.6) 0.00 (–2.8, 4.6) 0.00 (–3.0, 4.6)
Week 40 n = 210 n = 354 n = 564
Mean (SD) –0.30 (1.03) 0.03 (0.87) –0.10 (0.95)
Median (min, max) –0.20 (–3.8, 3.8) 0.00 (–3.4, 3.8) 0.00 (–3.8, 3.8)
Week 52 (4-weeks following last dose) n = 206 n = 350 n = 556
Mean (SD) –0.30 (1.00) 0.04 (0.96) –0.09 (0.99)
Median (min, max) –0.20 (–3.8, 2.6) 0.00 (–4.0, 4.0) 0.00 (–4.0, 4.0)
Week 60 (follow-up; 12 weeks following last dose)§ n ¼ 142 n ¼ 196 n ¼ 338
Mean (SD) 0.05 (1.19) 0.31 (1.08) 0.20 (1.13)
Median (min, max) 0.00 (–2.8, 4.8) 0.10 (–3.0, 3.6) 0.00 (–3.0, 4.8)
Prebronchodilator FEV1, change from baseline (mL)
†
Week 16 n ¼ 232 n ¼ 400 n ¼ 632
Mean (SD) 155 (384) 15 (340) 67 (363)
Median (min, max) 110 (–970, 1870) –5 (–1310, 1460) 30 (–1310, 1870)
Week 28 n ¼ 229 n ¼ 386 n ¼ 615
Mean (SD) 115 (451) 12 (379) 50 (410)
Median (min, max) 89 (–1950, 2540) 5 (–1660, 1760) 30 (–1950, 2540)
Week 52 (4 weeks following last dose) n ¼ 223 n ¼ 379 n ¼ 602
Mean (SD) 100 (448) –13 (374) 29 (406)
Median (min, max) 50 (–1210, 2460) –10 (–1580, 1400) 20 (–1580, 2460)
Blood eosinophil count (cells/mL)†
Week 4 n ¼ 228 n ¼ 399 n ¼ 627
Geometric mean (SD logs) 60 (0.886) 50 (0.948) 50 (0.931)
(continued)
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Table III. (continued).
Parameter
PPG
(n ¼ 237)
PMG
(n ¼ 414)
All Patients
(N ¼ 651)
Median (min, max) 70 (10, 1000) 50 (10, 1200) 60 (10, 1200)
Week 16 n ¼ 216 n ¼ 383 n ¼ 599
Geometric mean (SD logs) 50 (0.904) 50 (0.864) 50 (0.878)
Median (min, max) 60 (10, 400) 60 (10, 1100) 60 (10, 1100)
Week 28 n ¼ 224 n ¼ 378 n ¼ 602
Geometric mean (SD logs) 50 (0.871) 50 (0.941) 50 (0.915)
Median (min, max) 50 (10, 400) 50 (10, 700) 50 (10, 700)
Week 52 (4-weeks following last dose) n ¼ 217 n ¼ 373 n ¼ 590
Geometric mean (SD logs) 50 (0.979) 50 (0.909) 50 (0.934)
Median (min, max) 50 (10, 600) 50 (10, 900) 50 (10, 900)
Week 60 (follow-up; 12 weeks following last dose)§ n ¼ 148 n ¼ 200 n ¼ 348
Geometric mean (SD logs) 160 (1.117) 160 (1.141) 160 (1.129)
Median (min, max) 170 (10, 1900) 180 (10, 1200) 180 (10, 1900)
ACQ-5 ¼ Asthma Control Questionnaire–5; AE ¼ adverse event; ED ¼ emergency department; FEV1 ¼ forced expiratory
volume in 1 second; max ¼ maximum; min ¼ minimum; PMG ¼ previous mepolizumab group; PPG ¼ previous
placebo group.
*Analysis of exacerbation rate performed using a negative binomial model with covariates of region, exacerbations in the year
prior to MENSA7 or SIRIUS6 (as an ordinal variable) and % predicted FEV1 from the baseline of MENSA
7 or SIRIUS,6 with
logarithm of time on treatment as an offset variable.
†Baseline data on these end points are summarized in Table II.
‡A negative number represents improvement in asthma control.
§This time point was in the follow-up phase.
Clinical TherapeuticsFor the assessment of immunogenicity, within
COSMOS, marginally more (20 patients [9%]) in
the PPG had a positive ADA result postbaseline
compared with those in the PMG (11 patients
[3%]); positive ADA samples were infrequent, and
the levels were generally low and transient. All of
these patients were negative for neutralizing antibody.
In the post hoc analysis, treatment with mepolizumab
exerted a durable response over the open-label period. In
patients continuing to receive mepolizumab following
the MENSA study, the exacerbation rate per year
remained low across the double-blind and open-label
treatment periods (Figure 3). In patients who received
placebo in MENSA and mepolizumab in the open-label
period, the exacerbation rate decreased after the switch
to mepolizumab (Figure 3). On the assessment of
median OCS dose, the reduction in median OCS dose
achieved with mepolizumab during SIRIUS (10.0 mg/d
at baseline to 2.5 mg/d at the end of SIRIUS) was
maintained throughout the open-label period (Figure 4).2066In patients who received placebo during SIRIUS, the
median OCS dose was reduced from 12.3 mg/d at
baseline to 10.0 mg/d at the end of SIRIUS; this rate
was further reduced to 5.0 mg/d following 52 weeks
of mepolizumab treatment within the open-label
period (Figure 4). Additionally, in the group from
SIRIUS, 16/58 patients (28%) in the PPG and 18/57
(32%) in the PMG were no longer receiving OCS
treatment between weeks 48 and 52 (weeks 72–76
from SIRIUS baseline), compared with 6/61 (10%)
and 13/65 (20%) patients when commencing
COSMOS, respectively.DISCUSSION
COSMOS was a dedicated long-term safety study of
subcutaneous mepolizumab in patients with severe
eosinophilic asthma. Overall, results showed a favor-
able long-term safety proﬁle of subcutaneous mepoli-
zumab that was consistent with those from previouslyVolume 38 Number 9
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Figure 4. Summary of median oral corticosteroid
(OCS) doses during double-blind
(SIRIUS6) and open-label (COSMOS)
periods, by treatment allocation within
SIRIUS (as-treated [AT] popu-
lation; data combined with those
from the SIRIUS study). Display
includes only patients who completed
COSMOS. In total, 58 patients
received placebo in the double-blind
period and then received mepolizumab
during the open-label period; 57
patients received mepolizumab from
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through the open-label period.
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Figure 3. Exacerbation rate during double-blind
(MENSA7) and open-label (COSMOS)
periods, by treatment allocation within
MENSA7 (as-treated [AT] population;
data combined with those from the
MENSA study). Display includes only
patients who completed COSMOS. In
total, 159 patients received placebo in
the double-blind period and then
received mepolizumab during the
open-label period; 311 patients
received mepolizumab from the start
of the double-blind period through the
open-label period.
N. Lugogo et al.published studies.6,7 There was a low prevalences of
on-treatment AEs and SAEs considered related to the
study treatment (r20% and o1%, respectively), and
no reported mepolizumab-related anaphylactic reac-
tions or fatal AEs. Very few CV events, systemic
reactions, and local injection site reactions were
reported.
The prevalence of AEs in the open-label extension
compared favorably with those from the parent
MENSA and SIRIUS studies.6,7 In MENSA and
SIRIUS, the percentages of patients experiencing at
least 1 AE were similar between the PPG and PMG
groups, and these rates did not increase within this
52-week, open-label extension.6,7 Similarly, the rates
of AEs related to treatment did not increase over this
open-label extension compared with those from
MENSA and SIRIUS. Since biologic drugs such as
anti–interleukin-5 have the potential to invoke an
immune reaction,14 it was reassuring that there were
no cases of mepolizumab-related anaphylaxis, and
that the overall frequency of systemic reactionsSeptember 2016during the 52-week extension study was low (2%).
The immunogenicity data collected were consistent
with data from the DREAM, SIRIUS, and MENSA
studies,6–8 which demonstrated that the majority of
ADA-positive patients developed ADA within 16
weeks of the ﬁrst dose and that positivity decreased
over time.
Regarding efﬁcacy, a low prevalence of exacerba-
tions requiring hospitalization or an emergency
department visit was observed with mepolizumab treat-
ment, consistent with that observed with mepolizumab
during the MENSA and SIRIUS randomized controlled
studies.6,7 On-treatment exacerbation rates were also
similar between patients in the PMG and the PPG.
Mepolizumab treatment was shown to exert a durable
efﬁcacy response, with patients who previously received2067
Clinical Therapeuticsmepolizumab in MENSA or SIRIUS maintaining im-
provements in the reductions in the exacerbation rates
and OCS dosing throughout the open-label study.
One limitation of the SIRIUS study was the relatively
short duration of exposure to mepolizumab during the
double-blind period. A longer study would allow for
the determination of whether more complete with-
drawal of OCSs is possible and whether the outcomes
are maintained over time. Nonetheless, COSMOS
assessed OCS withdrawal in a limited number of
patients from SIRIUS and found that an additional 5
and 10 patients in the PMG and PPG, respectively,
were not receiving OCS treatment at the end compared
with the start of COSMOS. Importantly, in COSMOS,
clear improvements in exacerbation rates and OCS
dosing were observed during open-label treatment in
patients who previously received placebo. These data
indicate that the treatment effects of mepolizumab are
durable and stable over time.
It should be noted that the observed decreases in
OCS dosing achieved during the open-label period
were different from those observed in the SIRIUS
study.6 These differences may have been due to the
differences in the algorithms used to inform reductions
in dosing in each study; in SIRIUS,6 the algorithm was
protocol-driven (speciﬁed reductions in OCS dose on
the basis of asthma control and symptoms of adrenal
insufﬁciency),6 whereas in COSMOS, OCS reduction
was dependent on each physician’s judgment. Com-
bined with the open-label study design, the OCS dose
reduction observed during COSMOS may better
reﬂect the results that may be achieved in clinical
practice compared with those seen during SIRIUS.
The decreases in daily OCS dose seen in COSMOS
further support the beneﬁts of mepolizumab treatment
in providing a meaningful reduction in OCS dosing,
with the possibility of reducing the side effects
observed with long-term OCS treatment.10,11,15
Prebronchodilator FEV1 and ACQ-5 data in
COSMOS indicated an improvement in patients in the
PPG following the administration of mepolizumab
treatment. The scale of these improvements was con-
sistent with those observed in the MENSA and SIRIUS
studies.6,7 No further improvement in FEV1 or ACQ-5
was observed in the PMG. This observation suggests
that the improvements achieved are evident early after
the initiation of therapy and are stable over time, as per
the durability-of-response end points discussed earlier.
The interpretation of these long-term effects of2068mepolizumab on prebronchodilator FEV1, however,
should be made in the context of the expected decline in
lung function in this patient population, which may
vary between 20 and 50 mL/y.16–18 Potential changes
in treatment compliance should also be considered,
as increased disease stability from treatment may
lead to reduced treatment compliance with inhaled
medications.
Suppression of the eosinophil response is a clin-
ically relevant marker of efﬁcacy in the population
assessed during this study. A rapid, sustained reduc-
tion in blood eosinophils was observed in the PPG
following mepolizumab treatment; this trend is con-
sistent with those in the previous double-blind stud-
ies.6,7 This ﬁnding, together with the sustained
reduction in blood eosinophil count in the PMG,
suggests that the suppressive effect of mepolizumab
on interleukin-5 translates into a beneﬁcial effect in
this patient population, supported by the observed
beneﬁts on markers of asthma control. Of note, after
patients stopped treatment with mepolizumab, the
eosinophil counts started to increase at the follow-up
visit, along with markers of asthma control. This
expected response supports the need for long-term
use; however, further studies are needed to determine
whether a longer duration of treatment may modify
the course of the disease.
A limitation of this study was the lack of a control
arm; the open-label design used here means that any
between-study comparisons should be made with
caution. However, the observations from the
open-label period reﬂect in-practice data on patients
receiving treatment with mepolizumab.CONCLUSIONS
A safety proﬁle similar to that reported in previous
studies was observed during long-term (52-week) treat-
ment with subcutaneous mepolizumab.6,7 A durable and
stable response was also demonstrated through 84 weeks
of double-blind and open-label treatment. Patients pre-
viously on placebo and initiating mepolizumab treatment
in this open-label extension study demonstrated improve-
ments similar to those in MENSA and SIRIUS.
These ﬁndings support the long-term use of this medicine
in patients with severe eosinophilic asthma. Future long-
term studies during postmarketing surveillance in
clinical practice will further expand on the ﬁndings of
this study.Volume 38 Number 9
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Figure E1. Kaplan–Meier curve of time to first
exacerbation (AT population). Verti-
cal bars represent 95% CI. The ana-
lysis only includes exacerbations
experienced within the on-treatment
period; AT, as-treated; CI, confidence
intervals; PMG, previous mepolizumab
group; PPG, previous placebo group.
Table E1. Probability of an exacerbation (AT population
Time point
Probability
PPG (N¼237)
Week 16 26.9 (21.7, 33.0)
Week 32 41.6 (35.6, 48.3)
Week 52 50.5 (44.3, 57.1)
Kaplan–Meier estimates shown. The analysis only includes exac
as-treated; CI, conﬁdence intervals; PMG, previous mepolizuma
September 2016should be published in a timely manner. Authors were
in full editorial control of publication target journal,
content and conclusions and accepted full responsi-
bility for ﬁnal approval of a manuscript describing this
GSK sponsored research. The planning and develop-
ment of publications is a scientiﬁc and medical
function and GSK did not permit commercial staff
to participate in the design, conduct or publication of
human subject research. As agreed by authors before
the preparation of the manuscript began, authors were
provided with open and transparent access to data
supporting publications including access to data ta-
bles, ﬁnal study reports, case report forms and raw
data as needed. The manuscript was prepared in line
with Good Publication Practices: GSK does not pay
for authorship of peer reviewed articles or presenta-
tions, although GSK may reimburse reasonable ex-
penses associated with authorship or congress
presentations (e.g. travel expenses related to attend-
ance at author meetings or congress presenta-
tions). Notable exceptions are the use of professional
medical writers: If the authors request medical writing
support, this is fully disclosed in the conﬂict of
interests section in the manuscript.
Figure E1 and Table E1.)
of an exacerbation, % (95% CI)
PMG (N¼414) All patients (N¼651)
22.6 (18.8, 27.0) 24.2 (21.0, 27.7)
38.4 (33.9, 43.4) 39.6 (35.9, 43.6)
48.2 (43.4, 53.3) 49.1 (45.2, 53.1)
erbations experienced within the on-treatment period; AT,
b group; PPG, previous placebo group.2070.e1
